Constipation, a common gastrointestinal disorder, presents a significant challenge to healthcare professionals due to its multifactorial nature. Understanding its complexity is paramount to accurate diagnosis and effective treatment, thereby improving patient outcomes.
Constipation can be primarily due to slow colonic transit or anorectal dysfunction. It may also be secondary to systemic diseases or medications. A thorough understanding of the underlying pathophysiology aids in formulating a targeted treatment plan.
A comprehensive patient history and physical examination form the cornerstone of diagnosis. The Rome IV criteria can be used to diagnose functional constipation. Additional diagnostic tests, such as anorectal manometry, colon transit study, and defecography, can be employed based on clinical suspicion.
Treatment should be individualized and stepwise, starting with lifestyle modifications and dietary changes. If unsuccessful, bulk-forming agents, osmotic laxatives, or stimulant laxatives should be considered. For refractory cases, newer agents like secretagogues or prokinetic drugs can be utilized. In severe cases, surgical intervention may be necessary.
Management of constipation often requires a multidisciplinary team approach, involving gastroenterologists, surgeons, dietitians, and physiotherapists. This collaborative care model can enhance treatment outcomes and patient satisfaction.
Constipation is a complex disorder that requires a comprehensive approach for effective management. A clear understanding of its pathophysiology, coupled with a thorough diagnostic evaluation and a stepwise, individualized treatment plan, can lead to improved patient outcomes. Embracing a multidisciplinary care model can further enhance these results, highlighting the importance of collaboration in healthcare.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation